Literature DB >> 26824142

Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines.

Tanner K Hill1, Amanda L Davis, Frances B Wheeler, Sneha S Kelkar, Erica C Freund, W Todd Lowther, Steven J Kridel, Aaron M Mohs1.   

Abstract

Fatty acid synthase (FASN), the enzyme that catalyzes de novo synthesis of fatty acids, is expressed in many cancer types. Its potential as a therapeutic target is well recognized, but inhibitors of FASN have not yet been approved for cancer therapy. Orlistat (ORL), an FDA-approved lipase inhibitor, is also an effective inhibitor of FASN. However, ORL is extremely hydrophobic and has low systemic uptake after oral administration. Thus, new strategies are required to formulate ORL for cancer treatment as a FASN inhibitor. Here, we report the development of a nanoparticle (NP) formulation of ORL using amphiphilic bioconjugates that are derived from hyaluronic acid (HA), termed Nano-ORL. The NPs were loaded with up to 20 wt % weight of ORL at greater than 95% efficiency. The direct inhibition of the human recombinant thioesterase domain of FASN by ORL extracted from Nano-ORL was similar to that of stock ORL. Nano-ORL demonstrated a similar ability to inhibit cellular FASN activity when compared to free ORL, as demonstrated by analysis of (14)C-acetate incorporation into lipids. Nano-ORL treatment also disrupted mitochondrial function similarly to ORL by reducing adenosine triphosphate turnover in MDA-MB-231 and LNCaP cells. Nano-ORL demonstrated increased potency compared to ORL toward prostate and breast cancer cells. Nano-ORL decreased viability of human prostate and breast cancer cell lines to 55 and 57%, respectively, while free ORL decreased viability to 71 and 79% in the same cell lines. Moreover, Nano-ORL retained cytotoxic activity after a 24 h preincubation in aqueous conditions. Preincubation of ORL dramatically reduced the efficacy of ORL as indicated by high cell viability (>85%) in both breast and prostate cell lines. These data demonstrate that NP formulation of ORL using HA-derived polymers retains similar levels of FASN, lipid synthesis, and ATP turnover inhibition while significantly improving the cytotoxic activity against cancer cell lines.

Entities:  

Keywords:  Orlistat; fatty acid synthase; hyaluronic acid; nanoparticle; self-assembly; tetrahydrolipstatin

Mesh:

Substances:

Year:  2016        PMID: 26824142      PMCID: PMC4783219          DOI: 10.1021/acs.molpharmaceut.5b00447

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  38 in total

1.  HPLC analysis of orlistat and its application to drug quality control studies.

Authors:  Effat Souri; Hassan Jalalizadeh; Abbas Kebriaee-Zadeh; Bettina Zadehvakili
Journal:  Chem Pharm Bull (Tokyo)       Date:  2007-02       Impact factor: 1.645

Review 2.  Orlistat-associated adverse effects and drug interactions: a critical review.

Authors:  Theodosios D Filippatos; Christos S Derdemezis; Irene F Gazi; Eleni S Nakou; Dimitri P Mikhailidis; Moses S Elisaf
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 3.  Fatty acid synthase and cancer: new application of an old pathway.

Authors:  Francis P Kuhajda
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

4.  Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy.

Authors:  Ki Young Choi; Hong Yeol Yoon; Jong-Ho Kim; Sang Mun Bae; Rang-Woon Park; Young Mo Kang; In-San Kim; Ick Chan Kwon; Kuiwon Choi; Seo Young Jeong; Kwangmeyung Kim; Jae Hyung Park
Journal:  ACS Nano       Date:  2011-10-11       Impact factor: 15.881

5.  Overexpression of fatty acid synthase in human gliomas correlates with the WHO tumor grade and inhibition with Orlistat reduces cell viability and triggers apoptosis.

Authors:  Susanne Grube; Pedro Dünisch; Diana Freitag; Maren Klausnitzer; Yasser Sakr; Jan Walter; Rolf Kalff; Christian Ewald
Journal:  J Neurooncol       Date:  2014-05-01       Impact factor: 4.130

6.  Practical, catalytic, asymmetric synthesis of beta-lactones via a sequential ketene dimerization/hydrogenation process: inhibitors of the thioesterase domain of fatty acid synthase.

Authors:  Vikram C Purohit; Robyn D Richardson; Jeffrey W Smith; Daniel Romo
Journal:  J Org Chem       Date:  2006-06-09       Impact factor: 4.354

Review 7.  Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?

Authors:  Ruth Lupu; Javier A Menendez
Journal:  Curr Pharm Biotechnol       Date:  2006-12       Impact factor: 2.837

8.  Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice.

Authors:  Patricia M Alli; Michael L Pinn; Elizabeth M Jaffee; Jill M McFadden; Francis P Kuhajda
Journal:  Oncogene       Date:  2005-01-06       Impact factor: 9.867

9.  Inhibition of the thioesterase activity of human fatty acid synthase by 1,4- and 9,10-diones.

Authors:  Herman Odens; Todd Lowther; Steven Kridel; Laura Watts; Lauren Filipponi; Jeffrey Schmitt
Journal:  Chem Pharm Bull (Tokyo)       Date:  2014       Impact factor: 1.645

10.  DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Authors:  David S Wishart; Craig Knox; An Chi Guo; Savita Shrivastava; Murtaza Hassanali; Paul Stothard; Zhan Chang; Jennifer Woolsey
Journal:  Nucleic Acids Res       Date:  2006-01-01       Impact factor: 16.971

View more
  10 in total

1.  Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.

Authors:  Joshua J Souchek; Amanda L Davis; Tanner K Hill; Megan B Holmes; Bowen Qi; Pankaj K Singh; Steven J Kridel; Aaron M Mohs
Journal:  Mol Cancer Ther       Date:  2017-06-14       Impact factor: 6.261

2.  Probing the self-assembly dynamics and internal structure of amphiphilic hyaluronic acid conjugates by fluorescence spectroscopy and molecular dynamics simulations.

Authors:  Denis Svechkarev; Alexander Kyrychenko; William M Payne; Aaron M Mohs
Journal:  Soft Matter       Date:  2018-06-13       Impact factor: 3.679

3.  The role of hydrophobic modification on hyaluronic acid dynamics and self-assembly.

Authors:  William M Payne; Denis Svechkarev; Alexander Kyrychenko; Aaron M Mohs
Journal:  Carbohydr Polym       Date:  2017-11-08       Impact factor: 9.381

4.  ω-Hydroxy isoprenoid bisphosphonates as linkable GGDPS inhibitors.

Authors:  Nazmul H Bhuiyan; Michelle L Varney; Deep S Bhattacharya; William M Payne; Aaron M Mohs; Sarah A Holstein; David F Wiemer
Journal:  Bioorg Med Chem Lett       Date:  2019-08-20       Impact factor: 2.823

5.  Combination Therapy of Metastatic Castration-Recurrent Prostate Cancer: Hyaluronic Acid Decorated, Cabazitaxel-Prodrug and Orlistat Co-Loaded Nano-System.

Authors:  Zhen Qu; Yuning Ren; Hongyu Shen; Huihui Wang; Lijie Shi; Deyong Tong
Journal:  Drug Des Devel Ther       Date:  2021-08-20       Impact factor: 4.162

Review 6.  Tumour biology of obesity-related cancers: understanding the molecular concept for better diagnosis and treatment.

Authors:  Seong Lin Teoh; Srijit Das
Journal:  Tumour Biol       Date:  2016-09-14

7.  Hyaluronic acid formulation of near infrared fluorophores optimizes surgical imaging in a prostate tumor xenograft.

Authors:  Joshua J Souchek; Nicholas E Wojtynek; William M Payne; Megan B Holmes; Samikshan Dutta; Bowen Qi; Kaustubh Datta; Chad A LaGrange; Aaron M Mohs
Journal:  Acta Biomater       Date:  2018-06-08       Impact factor: 8.947

8.  Multimodal Imaging Nanoparticles Derived from Hyaluronic Acid for Integrated Preoperative and Intraoperative Cancer Imaging.

Authors:  William M Payne; Tanner K Hill; Denis Svechkarev; Megan B Holmes; Balasrinivasa R Sajja; Aaron M Mohs
Journal:  Contrast Media Mol Imaging       Date:  2017-09-11       Impact factor: 3.161

Review 9.  Lipogenesis inhibitors: therapeutic opportunities and challenges.

Authors:  Battsetseg Batchuluun; Stephen L Pinkosky; Gregory R Steinberg
Journal:  Nat Rev Drug Discov       Date:  2022-01-14       Impact factor: 112.288

Review 10.  Hyaluronic Acid within Self-Assembling Nanoparticles: Endless Possibilities for Targeted Cancer Therapy.

Authors:  Manuela Curcio; Orazio Vittorio; Jessica Lilian Bell; Francesca Iemma; Fiore Pasquale Nicoletta; Giuseppe Cirillo
Journal:  Nanomaterials (Basel)       Date:  2022-08-18       Impact factor: 5.719

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.